MKI67 and neoplasm: As shown in Figure 7, knockdown of CRNDE remarkably strengthened the sorafenib-mediated inhibition of xenograft tumor growth (Figures 7A–C) and decrease of the cell proliferation marker Ki67 (Figure 7D), while increased sorafenib-triggered cell apoptosis (Figure 7E) and PARP cleavage (Figure 7F).